The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s hepatorenal syndrome treatment market report forecasts the hepatorenal syndrome treatment market size to grow to $17.31 billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

Learn More On The Hepatorenal Syndrome Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

Hepatorenal Syndrome Treatment Market Size Forecast
The global hepatorenal syndrome treatment market size is expected to grow from $13.06 billion in 2022 to $13.85 billion in 2023 at a compound annual growth rate (CAGR) of 6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hepatorenal syndrome treatment market size is expected to reach $17.31 billion in 2027 at a CAGR of 5.7%.

North America held the largest hepatorenal syndrome treatment market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Hepatorenal Syndrome Treatment Market Driver ­– Increase In The Incidences Of Patients With Liver Damage Or Cirrhosis
According to a Fact Sheet released by the Centres for Disease Control and Prevention, a US-based Government body, the number of adults with confirmed liver disease in the US was 4.5 million in September 2022. Furthermore, according to Medscape, a medical information website, ALD-related fatalities increased by 17.6% between 2019 and 2021, while NAFLD-related deaths increased by 14.5%. As a result, the rising number of patients with liver damage or cirrhosis is propelling the hepatorenal syndrome treatment market forward.

Request for A Sample Of The Global Hepatorenal Syndrome Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp

Key Hepatorenal Syndrome Treatment Market Trend – Increasing In Research And Development Activities
Companies in the hepatorenal syndrome therapy market are currently focusing more on research and development in order to maintain their market position. For example, in September 2022, Mallinckrodt Pharmaceuticals, an Irish company specialising in developing, manufacturing, and distributing specialty products and therapies, announced FDA approval for Terlivaz, an injection that improves kidney function in adults with hepatorenal syndrome. The Phase 3 CONFIRM trial, the largest-ever prospective research (n=300) done in the United States and Canada to examine the safety and efficacy of terlipressin in patients with HRS type 1 (HRS-1) was a crucial role in the FDA’s approval. The primary outcome of the CONFIRM trial was verified HRS reversal, which was assessed as an improvement in renal function, avoidance of dialysis, and short-term survival (p=0.012).

Hepatorenal Syndrome Treatment Market Segment
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users

Hepatorenal Syndrome Treatment Market Major Players and Strategies
Major players in the hepatorenal syndrome treatment market are Becton, Dickinson and Company, BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC., ESP Pharma Inc., PharmaIN Corporation, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences limited, Mount Sinai, NYU Langone Health, and Max Healthcare.

The Hepatorenal Syndrome Treatment Global Market Report 2023 covers regional data on hepatorenal syndrome treatment market size, hepatorenal syndrome treatment market trends and drivers, opportunities, strategies, and hepatorenal syndrome treatment market competitor analysis. The countries covered in the hepatorenal syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

In patients with severe liver disease, hepatorenal syndrome (HRS) is a multiorgan condition characterised by acute kidney injury. When patients with this illness become oliguric, they exhibit signs and symptoms of liver failure as well as decreased urine.

View More Reports Related To The Hepatorenal Syndrome Treatment Market –
Polycystic Ovarian Syndrome Treatment Global Market Report 2023
Gardner Syndrome Treatment Global Market Report 2023
Wolff Parkinson White Syndrome Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: